Prasad Adusumilli, MD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the main challenges associated with poor efficacy of CAR-T cells in solid tumors, including limited infiltration by the effector T-cells, as well as the immunosuppressive microenvironment and heterogenous antigen expression. Following efficient infiltration in solid tumors with CAR-T cells, immune checkpoint blockade may be a viable approach to promote the functional persistence of CAR-T cells. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
